Leveraging the genetics of psychiatric disorders to prioritize potential drug targets and compounds.

doi:10.1038/s41386-026-02380-8

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Leveraging the genetics of psychiatric disorders to prioritize potential drug targets and compounds.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology - 1 Jun 2026

Parker Nadine, Koch Elise, Shadrin Alexey A, Fuhrer Julian, Hindley Guy F L, Stinson Sara E, Jaholkowski Piotr, Tesfaye Markos, Dale Anders M, Wingo Thomas S, Wingo Aliza P, Frei Oleksandr, O'Connell Kevin S, Smeland Olav B, Andreassen Ole A

Abstract excerpt

Genetics can inform biologically relevant drug development and repurposing, which may improve patient care. Here, we leverage the genetics of psychiatric disorders to prioritize potential drug targets and compounds. We used the genome-wide association studies of four psychiatric disorders [attention deficit hyperactivity disorder (ADHD), bipolar disorder, depression, and schizophrenia] and genes encoding drug...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Attention Deficit Disorder with Hyperactivity

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bipolar Disorder

Share to Drug Repositioning

Share to Genome-Wide Association Study

Share to Mental Disorders

Share to Proteomics

Share to Psychotropic Drugs

Share to Schizophrenia

Source

Open in PubMed Open full text

Identifiers

PMID: 41795042
DOI: 10.1038/s41386-026-02380-8
PMCID: PMC13212996

Genes

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Leveraging the genetics of psychiatric disorders to prioritize potential drug targets and compounds.PMID 41795042Read ↗

Leveraging the Genetics of Psychiatric Disorders to Prioritize Potential Drug Targets and CompoundsSemantic proximity Read ↗

Identifying drug targets for schizophrenia through gene prioritization.Semantic proximity Read ↗

Identifying drug targets for schizophrenia through gene prioritizationSemantic proximity Read ↗

When GWAS meets the Connectivity Map: drug repositioning for seven psychiatric disordersSemantic proximity Read ↗

Translating GWAS Findings Into Therapies For Depression And Anxiety Disorders: Drug Repositioning Using Gene-Set Analyses Reveals Enrichment Of Psychiatric Drug ClassesSemantic proximity Read ↗

Genetically informed drug target prioritisation and repurposing for major depressive disorderSemantic proximity Read ↗

Gene-set analysis based on the pharmacological profiles of drugs to identify repurposing opportunities in schizophrenia.Semantic proximity Read ↗

Psychiatric Genome-wide Association Study Enrichment Shows Promise for Future Psychopharmaceutical DiscoveriesSemantic proximity Read ↗

Psychiatric genome-wide association study enrichment shows promise for future psychopharmaceutical discoveriesSemantic proximity Read ↗

Mendelian Randomization Using the Druggable Genome Reveals Genetically Supported Drug Targets for Psychiatric Disorders.Semantic proximity Read ↗

Application of GWAS summary data and drug-induced gene expression profiles of neural progenitor cells in psychiatric drug prioritization analysis.Semantic proximity Read ↗

Genome-wide Mendelian randomization identifies actionable novel drug targets for psychiatric disorders.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.